



Additional FDA VRBPAC Dates

- Oct. 14, the FDA VRBPAC committee will discuss an amendment to the emergency use authorization of the [Moderna COVID-19 Vaccine](#) for the administration of a booster dose, in individuals 18 years of age and older.
- Oct. 15, the VRBPAC will discuss amending the emergency use authorization of Johnson and Johnson's [Janssen COVID-19 Vaccine](#) for the administration of a booster dose, in individuals 18 years of age and older.
- On Oct. 15, the committee will discuss heterologous use of booster doses following the primary series of the three currently authorized or approved COVID-19 vaccines.
- On October 26, FDA VRBPAC will meet to review Pfizer data on 5-11 year olds





ACIP Planned Meeting Dates

- Oct. 20-21*: Will include review of anticipated FDA regulatory action for booster doses for those who received Moderna or Janssen/J&J products and for heterologous booster dose use
- Nov. 2-3*: Will include review of anticipated FDA regulatory action on Pfizer data for children 5-11 years of age
- Both meetings are tentatively scheduled from 10am – 5pm ET
- Draft agendas and presentation slides will be posted at <https://www.cdc.gov/vaccines/acip/> once available

* Dates subject to change

Pfizer Products for November 2021

Description	Current Adult/Adolescent Formulation (1170 and 450 packs)	Future Pediatric Formulation
	<i>Dilute Prior to Use</i>	<i>Dilute Prior to Use</i>
Age Group	12 years and older	5 to <12 years**
Vial Cap Color	PURPLE 	ORANGE 
Dose	30 mcg	10 mcg
Injection Volume	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	10 doses per vial (after dilution)
Storage Conditions		
ULT Freezer (-90°C to -60°C)	9 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks